Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer-Reference-Cited by-同舟云学术

Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer

Published:2022-02-16 Issue:2 Volume:2022 Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Tattersall Abigail¹,Ryan Neil²³,Wiggans Alison J⁴,Rogozińska Ewelina⁵,Morrison Jo⁶

Affiliation:

1. Kingston Hospital NHS Foundation Trust; Kingston upon Thames UK

2. The Academic Women’s Health Unit, Translational Health Sciences, Bristol Medical School; University of Bristol; Bristol UK

3. Department of Obstetrics and Gynaecology; St Michael’s Hospital, Bristol, UK; Bristol UK

4. Department of Gynaecological Oncology; Cheltenham General Hospital, Glocestershire Hospitals NHS Foundation Trust; Cheltenham UK

5. The Evidence-Based Medicine Consultancy Ltd; Bath UK

6. Department of Gynaecological Oncology, GRACE Centre; Musgrove Park Hospital, Somerset NHS Foundation Trust; Taunton UK

Publisher

Wiley

Subject

Pharmacology (medical)

Reference306 articles.

1. A study of rucaparib as switch maintenance following platinum-based chemotherapy in patients with platinum-sensitive, high-grade serous or endometrioid epithelial ovarian, primary peritoneal or fallopian tube cancer (ARIEL3) ClinicalTrials.gov website https://clinicaltrials.gov/ct2/show/NCT01968213?term=NCT01968213&rank=1

2. ARIEL3: a phase 3, randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian cancer (OC);Coleman;Clinical Cancer Research,2018

3. Coleman RL Oza AM Lorusso D Aghajanian C Oaknin A Dean A ARIEL3: a phase 3, randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian cancer (OC) Clinical Cancer Research 2018 PR06

4. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial [Erratum appears in Lancet. 2017 Oct 28;390(10106):1948; PMID: 29115226];Coleman;Lancet,2017

5. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial [Erratum appears in Lancet. 2017 Oct 28;390(10106):1948; PMID: 29115226];Coleman;Lancet (london, England),2017

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. New horizons for platinum-resistant ovarian cancer: insights from the 2023 American Society of Clinical Oncology (ASCO) and European Society for Medical Oncology (ESMO) Annual Meetings;International Journal of Gynecologic Cancer;2023-12-14

2. Expanding the Role of Boron in New Drug Chemotypes: Properties, Chemistry, Pharmaceutical Potential of Hemiboronic Naphthoids;Journal of Medicinal Chemistry;2023-09-26

3. Evaluation of follow-up strategies for women with epithelial ovarian cancer following completion of primary treatment;Cochrane Database of Systematic Reviews;2023-08-31

4. Neoadjuvant Chemotherapy plus Interval Cytoreductive Surgery with or without Hyperthermic Intraperitoneal Chemotherapy (NIHIPEC) in the Treatment of Advanced Ovarian Cancer: A Multicentric Propensity Score Study;Cancers;2023-08-26

5. Cost-effectiveness of maintenance niraparib with an individualized starting dosage in patients with platinum-sensitive recurrent ovarian cancer in China;Frontiers in Pharmacology;2023-07-27